HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

ausing bone marrow dysfunction and enlargement of the lymph nodes, liver and spleen. Standard front line therapy consists of alkylating agent based drug regimens. Fludarabine is the only approved drug for the treatment of patients who have failed alkylating agents. No approved therapy is available for patients who fail fludarabine therapy.

CAMPATH appears to work in CLL by depleting malignant CLL cells, which bear the CD52 antigen. CAMPATH is a humanized monoclonal antibody which is directed against the CD52 antigen found on normal and malignant lymphocytes, on normal macrophages and monocytes, but has not been detected on hematopoietic stem cells.

CAMPATH therapy is associated with significant lymphopenia. The lymphopenia resolves in some, but not all, patients over weeks to months after cessation of CAMPATH therapy.

"Early studies suggested the promise of CAMPATH. This study appears to confirm the decision to submit a BLA to the FDA," said Kanti R. Rai, M.D., Chief, Division Hematology-Oncology, Long Island Jewish Medical Center. "CAMPATH may very well become the next new and promising monoclonal antibody therapy for patients with cancer. For our patients with CLL, CAMPATH may change the expectation from one of relentlessly progressive deterioration on palliative therapies to the hope of extended survival," said Dr. Rai, who is also one of the trial's principal investigators and an internationally recognized expert in CLL.

ILEX and LeukoSite are developing CAMPATH through a joint venture that was established in May 1997. Clinical trials in the treatment of non-Hodgkin?s lymphoma, CLL, and other malignancies expressing CD52 are being planned.

"CAMPATH is the most advanced of ILEX's nine compounds and we are anxious to make it available to patients," said Richard L. Love, president and chief executive officer of ILEX.

ILEX Oncology, Inc. is a drug development company focused exclusively on accelerated development of drugs fo
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... ... , ... On Saturday, October 21, the Health & Wellness Center at Florida ... money for the American Heart Association Heart Walk. Teams of up to 10 people ... keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/22/2017)... Md. , Sept. 22, 2017  As the ... Republican Senators Bill Cassidy (R-LA) and ... Information notes that the medical device industry is in ... medical device tax, the 2.3% excise tax on medical ... But they also want covered patients, increased visits and ...
Breaking Medicine Technology:
Cached News: